Abstract 1497
Background
We report an analysis of Asian vs non-Asian pts with CRZ-refractory, ALK+ NSCLC from ALTA (NCT02094573).
Methods
Pts were stratified by presence of baseline (BL) CNS metastases and best response to prior CRZ and randomized 1:1 to BRG 90 mg qd (arm A) or 180 mg qd with a 7-day lead-in at 90 mg (arm B). Primary endpoint: Investigator-assessed confirmed ORR by RECIST v1.1.
Results
222 pts were randomized; 69 Asian (A/B, n = 39/30), 153 non-Asian (n = 73/80); median age: Asian, 50/56 y; non-Asian, 51/57 y; 85/70% vs 64/66% had BL CNS metastases. As of Sep 2017, median follow-up was 18.4/22.5 mo (A/B) in Asians vs 22.3/24.5 mo in non-Asians. In Asians, median IRC-assessed PFS (mo) was 9.1 (95% CI 5.6–18.2) in A vs 15.6 (9.2–21.2) in B (HR 0.88 [95% CI 0.48–1.62]; P = 0.6808); in non-Asians, PFS (A/B) was 9.9 (9.0–26.3) vs 17.9 (11.6–23.9; HR 0.72 [0.45–1.13]; P = 0.1510) (Table). Of 7/2 (A/B) Asian pts with measurable BL CNS metastases, 3/1 had confirmed intracranial objective responses; in non-Asian pts with measurable BL CNS metastases, IRC-assessed iORR was 53/69% (n = 19/16). In Asians (A vs B) with any BL CNS metastases, IRC-assessed median iPFS (mo) was 15.6 (5.6–18.4) vs 12.8 (7.3–21.1); in non-Asians, 12.8 (7.4–NR) vs 20.7 (11.1–NR). Most common any-grade TRAEs in Asians (≥20%): increased CPK and amylase; in non-Asians, nausea, diarrhea, and increased CPK. Most common grade ≥3 TRAEs (>3%) in Asians: increased CPK; in non-Asians, increased CPK and lipase, hypertension. Early-onset pulmonary AEs occurred in 3 (4%; 1 grade ≥3) Asian (Korean) and 11 (7%; 6 grade ≥3) non-Asian pts. Dose reductions due to AE: 7.7/30.0% in Asian pts; 7.1/28.8% in non-Asian pts; discontinuations due to AE: 7.7/16.7% in Asian pts; 10.0/20.0% in non-Asian pts.Table:
1543P
Investigator-Assessed | Independent Review Committee (IRC)–Assessed | |||||||
---|---|---|---|---|---|---|---|---|
Asian (n = 69) | Non-Asian (n = 153) | Asian (n = 69) | Non-Asian (n = 153) | |||||
Arm A (n = 39) | Arm B (n = 30) | Arm A (n = 73) | Arm B (n = 80) | Arm A (n = 39) | Arm B (n = 30) | Arm A (n = 73) | Arm B (n = 80) | |
Confirmed ORR, % | 49 (30–67a) | 67 (45–84a) | 44 (31–58a) | 53 (40–65a) | 56 (40–72b) | 67 (47–83b) | 48 (36–60b) | 53 (41–64b) |
Median DoR in responders,c mo | 13.7 (5.6–19.4b) | 13.8 (10.2–14.8b) | 9.5 (7.4–NRb) | 16.6 (9.0–24.0b) | 16.4 (5.6–24.9b) | 13.9 (7.4–19.4b) | 24.6 (7.4–NRb) | 15.7 (12.6–30.2b) |
Median PFS,c mo Events, % | 9.2 (5.6–15.6b) 69 | 15.6 (11.1–15.7b) 60 | 9.2 (5.7–11.1b) 69 | 14.7 (10.8–24.0b) 58 | 9.1 (5.6–18.2b) 67 | 15.6 (9.2–21.2b) 60 | 9.9 (9.0–26.3b) 53 | 17.9 (11.6–23.9b) 45 |
OSc Median, mo 1-y,c % 2-y,c % | NR (18.2–NRb) 77 (60–88b) 56 (37–72b) | NR (NR–NRb) 92 (73–98b) 79 (57–91b) | 29.5 (14.5–NRb) 67 (54–76b) 53 (41–64b) | 34.1 (22.6–NRb) 76 (65–84b) 62 (50–71b) | – – – | – – – | – – – | – – – |
DoR, duration of response; NR, not reached; ORR, objective response rate; OS, overall survival; PFS, progression-free survival. a97.5% CI (primary endpoint); b95% CI; cKaplan-Meier estimate.
Conclusions
BRG showed comparable efficacy and acceptable safety in Asians and non-Asians in CRZ-refractory ALK+ NSCLC, with nonsignificant, numerically improved PFS at the 180-mg (with lead-in) dose.
Clinical trial identification
NCT02094573.
Editorial acknowledgement
Peloton Advantage, LLC, an OPEN Health Company, funded by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Legal entity responsible for the study
ARIAD Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Funding
ARIAD Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Disclosure
D.H. Lee: Honoraria (self): AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, ChongKunDang, CJ Healthcare, Eli Lilly, Genexine, Janssen, Merck, MSD, Mundipharma, Novartis, Ono, Pfizer, Roche, Samyang Biopharm, ST Cube, Takeda. D. Kim: Research grant / Funding (institution): Alpha Biopharma, Astrazeneca/MedImmune, Hanmi, Janssen, Merus, Mirati Therapeutics, MSD, Novartis, ONO Pharmaceutical, Pfizer, Roche/Genentech, Takeda, TP Therapeutics, Xcovery, Yuhan. D.R. Camidge: Honoraria (self): AstraZeneca, Takeda, Genoptix, G1 Therapeutics [DSMB], Mersana Therapeutics, Roche, Ignyta, Daiichi Sankyo [ILD adjudication committee], Hansoh SRC, Bio-Thera DSMB, Lycera, Revolution Med; Research grant / Funding (self): Takeda. C.J. Langer: Honoraria (self): Bristol-Myers Squibb, Eli Lilly, Roche/Genentech; Advisory / Consultancy: Abbott, ARIAD, AstraZeneca, Bayer/Onyx, Bristol-Myers Squibb, Cancer Support Community, Celgene, Clarient, Clovis Oncology, Eli Lilly, Merck, Roche/Genentech, Takeda; Research grant / Funding (self): Advantagene, ARIAD, Celgene, Clovis Oncology, GlaxoSmithKline, Inovio, Merck, Roche/Genentech, Stemcentrx; Advisory / Consultancy: Amgen, Lilly, Peregrine Pharmaceuticals, Synta. R.M. Huber: Honoraria (self): ARIAD, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Roche; Advisory / Consultancy: Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Clovis Oncology, Eli Lilly, Novartis, Roche; Research grant / Funding (self): Pierre Fabre. M. Tiseo: Advisory / Consultancy, Speaker Bureau / Expert testimony: AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, MSD, Novartis, Otsuka, Pfizer, Pierre Fabre, Roche. H.L. West: Advisory / Consultancy: AbbVie, ARIAD, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Merck, PharmaMar, Roche/Genentech, Spectrum, Takeda; Speaker Bureau / Expert testimony: ARIAD, Bristol-Myers Squibb, Roche/Genentech. H.J.M. Groen: Advisory / Consultancy: AbbVie, BMS, Eli Lilly, MSD, Novartis, Pfizer, Roche/Genentech; Research grant / Funding (self): Eli Lilly, Roche. K.L. Reckamp: Advisory / Consultancy: Amgen, ARIAD, Astellas, Takeda, Tesaro; Research grant / Funding (self): Adaptimmune, ARIAD, BMS, Boehringer Ingelheim, AbbVie, Novartis, Pfizer, Roche/Genentech, Xcovery. M.J. Hochmair: Honoraria (self): AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme, Pfizer, Roche, Takeda; Advisory / Consultancy: Boehringer Ingelheim, Merck Sharp & Dohme, Novartis, Roche, Takeda. N.B. Leighl: Travel / Accommodation / Expenses: AstraZeneca, BMS, MSD, Pfizer. K.H. Hansen: Honoraria (self): AstraZeneca, Boehringer Ingelheim, Lilly, Novartis, Roche; Advisory / Consultancy: AstraZeneca, BMS, Boehringer Ingelheim, Lilly, MSD, Roche; Travel / Accommodation / Expenses: BMS, Boehringer Ingelheim, MSD, Pfizer, Roche. S.N. Gettinger: Advisory / Consultancy: Alexion Pharmaceuticals, ARIAD, Bristol-Myers Squibb, Pfizer; Research grant / Funding (self): ARIAD, Bristol-Myers Squibb, Incyte, Pfizer, Roche/Genentech. L. Paz-Ares: Honoraria (self), Spouse / Financial dependant: Eli Lilly, MSD, BMS, Roche, PharmaMar, Merck, AstraZeneca, Novartis, Boehringer Ingelheim, Celgene, Servier, Sysmex, Amgen, Incyte, Pfizer, Ipsen, Adacap, Sanofi, Bayer, Blueprint; Officer / Board of Directors: Genomica; Research grant / Funding (institution): MSD, BMS, AstraZeneca, Pfizer. E.S. Kim: Advisory / Consultancy: AstraZeneca, Celgene, Eli Lilly; Honoraria (self): Eli Lilly, AstraZeneca, Celgene. E.F. Smit: Advisory / Consultancy: Eli Lilly; Research grant / Funding (self): AstraZeneca, Bayer, Boehringer Ingelheim, Roche/Genentech. Q. Ni: Full / Part-time employment: Takeda. P. Zhang: Full / Part-time employment: Takeda. M. Ahn: Honoraria (self): AstraZeneca, Boehringer Ingelheim, Lilly, MSD; Advisory / Consultancy: AstraZeneca, Boehringer Ingelheim, Lilly, MSD. All other authors have declared no conflicts of interest.
Resources from the same session
3345 - Escalation plans and DNACPR discussions in the unwell oncology patient
Presenter: Raghad Elghadi
Session: Poster Display session 1
Resources:
Abstract
4165 - The Relation between the Symptom Burden of Hospitalized Patients with Incurable Cancer and the Quality-of-Life of Their Family Caregivers
Presenter: Eman Tawfik
Session: Poster Display session 1
Resources:
Abstract
1784 - Clinical predictors for analgesic response to radiotherapy in patients with painful bone metastases
Presenter: Ragnhild Habberstad
Session: Poster Display session 1
Resources:
Abstract
5323 - 30-Day Mortality in Palliative Radiotherapy
Presenter: Shing Fung Lee
Session: Poster Display session 1
Resources:
Abstract
3942 - The relationship between Naldemedine administration and the maximum dose of oral opioids
Presenter: Shinya Kajiura
Session: Poster Display session 1
Resources:
Abstract
3698 - Exposure to low energy amplitude modulated radiofrequency electromagnetic fields (EMF) is associated with rapid improvement in quality of life (QoL) status in patients with advanced hepatocellular carcinoma (HCC), using various analyses of EORTC-C30.
Presenter: Elizabeth Santana
Session: Poster Display session 1
Resources:
Abstract
3885 - Olanzapine Combined with 5-HT3 RA Plus Dexamethasone for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting in High and Moderate Emetogenic Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Presenter: Jian-Guo Zhou
Session: Poster Display session 1
Resources:
Abstract
5700 - Early Palliative care in advanced cancer, is it really effective?
Presenter: Raquel Gómez Bravo
Session: Poster Display session 1
Resources:
Abstract
5924 - Deprescribing Potentially Inappropriate Medication in Cancer Patients
Presenter: Simon Reuter
Session: Poster Display session 1
Resources:
Abstract
5314 - Spirituality and religious coping for Cancer patients and providers: An ‘Almighty’ belief for palliative care
Presenter: Vibhay Pareek
Session: Poster Display session 1
Resources:
Abstract